Redefining What’s Possible in MRD
Oct 20, 2026
View online
Redefining What’s Possible in MRD
C. S. Pramesh Has Been Elected UICC President-Elect for the 2026–2028 Term
FDA Grants Accelerated Approval: Dostarlimab for MSI-H/dMMR Locally Advanced Rectal Cancer
RASolve 308: Phase III Trial Tests Zoldonrasib With Pembrolizumab and Chemotherapy in First-Line RAS G12D NSCLC
Arif Kamal: Excited to Join Pfizer as Chief Oncology Medical Officer
ESMO 2026: 5 Phase III Immunotherapy Trials to Watch
Caregiver Burnout – An Unrecognised Challenge in Oncology
Bari, 1943: The Disaster That Changed Cancer Treatment
A Defining Moment for Cancer Immunotherapy During ESMO 2026 – Agenus
Cancer Research Institute — IGNITE Award 2027
Pediatric Cancer Foundation — Research Grants 2027
Unsubscribe
|
Manage subscription
OncoDaily, P53 Inc.
867 Boylston Street, 5th Floor, Suite 1094, Boston, MA 02116
Copyright (C) 2023-2026. OncoDaily, P53 Inc. All rights reserved.
